Page 39 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 39
Prospective DPYD genotyping: ready for prime time
FDA.gov. Accessed 29 July 2015.
66. EMA. European Medicines Agency. Xeloda (capecitabine): EPAR, product information. 2015;
2
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000316/
human_med_001157.jsp&mid=WC0b01ac058001d124. Accessed 29 July 2015.
67. Schmoll HJ, Van CE, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol.
2012;23(10):2479-2516.
68. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium
guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin
Pharmacol Ther. 2013;94(6):640-645.
69. KNMP. Pharmacogenetics Working Group of the Royal Dutch Society for the Advancement of
Pharmacy. [Background information on DPD pharmacogenetics]. 2014; http://www.knmp.nl/ downloads/g-standaard/farmacogenetica/Algemene-achtergrondtekst-Farmacogenetica-2013- Dihydropyrimidine-Dehydrogenase.pdf. Accessed 29 July 2015.
70. van Gils CW, de GS, Tan SS, et al. Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care. 2015;24(3):321-332.
71. von Borstel R, O’Neil JD, Saydoff JA, Bamat MK. Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency. J Clin Oncol. 2010;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago: 20 May 2010.
37
